A 71‐year‐old man with a history of 6 weeks of generalised decline presented for outpatient clinic assessment. Initial symptoms included fatigue, weakness, and anorexia causing 6 kg weight loss. His medical history was significant for a live‐related renal transplant 20 years earlier for membranous glomerulonephritis, insulin‐dependent type 2 diabetes mellitus, a right native nephrectomy 12‐months prior for clear cell renal cell carcinoma (Grade 3, pT1a), and multiple basal and squamous cell carcinomas of the skin. Maintenance immunosuppression was with mycophenolate mofetil 1 g twice a day and cyclosporine 50 mg twice a day without prednisolone. He had received one infusion of rituximab 800 mg 4 months earlier for biopsy‐proven recurrent membranous glomerulonephritis. Further history and examination did not reveal any localising symptoms or signs.
The full article is accessible to AMA
members and paid subscribers.
Login to MJA or subscribe now.
- 1. Permpalung N, Kittipibul V, Mekraksakit P, et al. A comprehensive evaluation of risk factors for Pneumocystis jirovecii pneumonia in adult solid organ transplant recipients: a systematic review and meta‐analysis. Transplantation 2021; 105: 2291‐2306.
- 2. Kamanski H, Belliere J, Burguet L, et al. Identification of predictive markers and outcomes of late‐onset Pneumocystis jirovecii pneumonia in kidney transplant recipients. Clin Infect Dis 2020; 73: 1456‐1463.
- 3. Park JW, Curtis JR, Jun KI et al. Primary prophylaxis for Pneumocystis jirovecii pneumonia in patients receiving rituximab. Chest 2022; 161: 1201‐1210.
- 4. Hamroun A, Lenain R, Nguyen LB et al. Hypercalcemia is common during Pneumocystis pneumonia in kidney transplant recipients. Nature 2019; 9: 12508.
- 5. Tebben PJ, Ravinder JS, Kumar R. Vitamin D‐mediated hypercalcemia: mechanisms, diagnosis, and treatment. Endocr Rev 2016; 37; 521‐547.
No relevant disclosures.